IMS Capital Management lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 451.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,134 shares of the biopharmaceutical company’s stock after buying an additional 53,321 shares during the period. Pfizer makes up 2.2% of IMS Capital Management’s portfolio, making the stock its 7th biggest position. IMS Capital Management’s holdings in Pfizer were worth $3,415,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of PFE. Norges Bank purchased a new stake in shares of Pfizer during the fourth quarter valued at $3,351,891,000. Capital International Investors boosted its position in Pfizer by 3,059.6% in the first quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock worth $1,994,698,000 after purchasing an additional 37,310,556 shares during the last quarter. Vanguard Group Inc. boosted its position in Pfizer by 3.0% in the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock worth $24,801,210,000 after purchasing an additional 13,790,348 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Pfizer by 577.8% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after purchasing an additional 10,440,786 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Pfizer by 28.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock worth $2,246,359,000 after purchasing an additional 9,537,621 shares during the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.
Pfizer Stock Up 1.5 %
Shares of PFE opened at $44.57 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.20 and a debt-to-equity ratio of 0.39. Pfizer Inc. has a 12-month low of $40.94 and a 12-month high of $61.71. The business’s 50 day moving average is $48.40 and its 200 day moving average is $50.33. The company has a market capitalization of $250.14 billion, a PE ratio of 8.72, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.59%. Pfizer’s payout ratio is 31.31%.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. Morgan Stanley dropped their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research report on Friday, July 8th. Barclays set a $50.00 target price on Pfizer in a research report on Thursday, September 1st. The Goldman Sachs Group set a $50.00 target price on Pfizer in a research report on Thursday, September 1st. Berenberg Bank set a $44.00 price objective on Pfizer in a research report on Wednesday, September 14th. Finally, JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research report on Tuesday, June 28th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.